HIMS Earnings Preview: Will The Stock Rebound After 25% Drop?
Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25% on Friday, Feb 21, after the U.S. FDA announced semaglutide is no longer in shortage.
Why Is HIMS Stock Dropping Today?
The U.S. FDA has officially declared that Novo Nordisk’s (NVO) popular diabetes and weight loss therapies, Ozempic and Wegovy, are no longer in
Hims & Hers Stock Plummets. The Wegovy Shortage Is Over.
The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
HIMS Stock To Rise >100% Again?
We believe there is minimal cause for concern with HIMS stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely
Why Is HIMS Stock Down So Much? Should You Buy?
HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss drugs like Ozempic and Wegovy, which previously allowed Hims & Hers to sell compounded alternatives. Compounded versions were permitted during the shortage but are now restricted unless they meet specific exceptions.
Why Hims & Hers Health Stock Is Plummeting Today
Shares of Hims & Hers Health ( HIMS -24.30%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as much as 26.1% earlier in the day. The move comes as the S&P 500 lost 1% and the Nasdaq Composite lost 1.3%.
What's Going On With Hims & Hers Health Stock Today?
Hims & Hers Health acquired a peptide facility to strengthen its U.S. supply chain and meet demand for personalized treatments. Also, in another development, FDA resolves semaglutide injection shortage.
Why Hims & Hers Health, Inc. (HIMS) Crashed on Friday
We recently compiled a list of the 10 Stocks Record Biggest Double-Digit Drop on Friday. In this article, we are going to ...
Hims & Hers Health (HIMS) Upward Trajectory Boosted by Recent Acquisition
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Hims Expands Drug Manufacturing With California Peptide Plant Acquisition
Hims & Hers Health Inc. has acquired a California-based manufacturing facility to expand its range of peptide treatments, ...
Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply
Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...
Why Hims & Hers Stock Dropped Today
Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...
Hims & Hers to offer at-home blood draws, lean into 'peptide innovations' with new acquisitions
The startup is expanding its services less than one year after it started offering compounded GLP-1 weight loss drugs.
Business Wire1d
Hims & Hers Acquires US-based Peptide Facility
Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company’s lon ...